(R)-4-(4-ethyl-2-oxooxazolidin-3-yl)benzoic acid → (R)-3-{4-[4-(3,5-dimethylpyridin-2-yl)piperazine-1-carbonyl]phenyl}-4-ethyloxazolidin-2-one
반응식
[CH2:1]([C@@H:3]1[CH2:7][O:6][C:5](=[O:8])[N:4]1[C:9]1[CH:17]=[CH:16][C:12]([C:13]([OH:15])=O)=[CH:11][CH:10]=1)[CH3:2].Cl.[CH3:19][C:20]1[C:21]([N:27]2[CH2:32][CH2:31][NH:30][CH2:29][CH2:28]2)=[N:22][CH:23]=[C:24]([CH3:26])[CH:25]=1>>[CH3:19][C:20]1[C:21]([N:27]2[CH2:28][CH2:29][N:30]([C:13]([C:12]3[CH:11]=[CH:10][C:9]([N:4]4[C@H:3]([CH2:1][CH3:2])[CH2:7][O:6][C:5]4=[O:8])=[CH:17][CH:16]=3)=[O:15])[CH2:31][CH2:32]2)=[N:22][CH:23]=[C:24]([CH3:26])[CH:25]=1참가 물질
3
실험 절차
By reaction and treatment in the same manner as in Example 49 and using (R)-4-(4-ethyl-2-oxooxazolidin-3-yl)benzoic acid (470 mg) described in Preparation Example 78 and 1-(3,5-dimethylpyridin-2-yl)piperazine hydrochloride (455 mg) described in Preparation Example 64, the title compound (312 mg) was obtained.
후처리
- customBy reaction and treatment in the same manner as in Example 49